Developing a new cancer immunotherapy, SurVaxM from bench to bedside

MimiVax, Inc. is developing immunotherapeutic vaccines and targeted therapies for treating cancers and preventing recurrence. The company’s lead agent, SurVaxM, targets survivin, a cell-survival protein expressed in cancer cells.

Read more in Nature BioPharma Dealmakers